Trial Profile
A Retrospective Study Among Patient Receiving Myelosuppressive Chemotherapy for Solid Tumors or Non-Hodgkin's lymphoma (NHL)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2019
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary) ; Pegfilgrastim (Primary)
- Indications Breast cancer; Colon cancer; Colorectal cancer; Lung cancer; Non-Hodgkin's lymphoma; Rectal cancer
- Focus Therapeutic Use
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 13 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology